Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited Earnings Recaps

TAK Health Care 2 recaps
Q4 2026 May 14, 2026

Shares in Takeda edged up modestly by 1.3%, reflecting a steady fiscal year 2025 performance that balanced ongoing LOE headwinds and pipeline progress, without clear market conviction on near-term growth catalysts.

Key takeaways
  • Core revenue was approximately JPY 4.5 trillion, partly pressured by loss of exclusivity in mature products.
  • Core operating profit reached around JPY 1.17 trillion, supported by robust cost management and efficiency measures.
  • Takeda delivered positive Phase III data for multiple late-stage assets, including oveporexton, rusfertide, and zasocitinib, setting the stage for potential regulatory approvals and launches in 2026.
  • The pipeline was further strengthened with Phase III starts for elritercept and mezagitamab, and strategic oncology partnerships expanded future growth opportunities.
  • Management emphasized disciplined commercial execution alongside innovation, signaling focus on upcoming launches amid a pivot to an evolved operating model to drive efficiency and sustainability.
Full recap
Q3 2026 Jan 30, 2026

Takeda's Q3 FY '25 results reflect resilient fundamentals despite the ongoing impacts from VYVANSE generic erosion, with promising advancements in their late-stage pipeline expected to drive future growth.

Key takeaways
  • Revenue for the first nine months decreased 3.3% to over JPY 3.4 trillion, with core operating profit down 3.4% year-on-year, but showing improvement from H1.
  • Growth and launch products contributed over 50% of total revenue, growing 6.7% at constant exchange rates, signaling a rebound in the latter half of the fiscal year.
  • Significant product advancement: Regulatory filings for key assets oveporexton and rusfertide completed, with expected launches within the next 18 months, potentially transforming treatment standards in their respective markets.
  • Strong cash flow reported at JPY 625.9 billion, indicating prudent financial management amidst product transitions.
  • Pipeline expansion with potential from new strategic partnerships, enhancing long-term growth trajectories beyond generic erosion impacts.
Full recap